Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells

Banerjee, Shreya; Kambhampati, Suman; Haque, Inamul

doi:10.1007/s12079-011-0138-y

Cited by 26 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At standard dosages, Tam has minimal or no effect on Tam-resistant breast cancer cells (27). At higher concentrations of Tam beyond the dose that promotes tumor growth The level of Gαѕ was reduced to <50% of the control levels in the cells transfected with oligos specific for Gαѕ.…”

Section: Discussionmentioning

confidence: 96%

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways

et al. 2013

View full text Add to dashboard Cite

The majority of breast cancers undergo progression from an initially endocrine responsive phenotype to an endocrine therapy-resistant phenotype, and acquired resistance to tamoxifen (Tam) is a major clinical problem. In the present study, we aimed to identify the function and mechanism of Tam at different concentrations in cells with acquired Tam resistance. Estrogen-dependent MCF-7 cells were cultured with Tam to generate Tam-resistant (TAM-R) breast cancer cells or in estrogen-free medium to mimic the effects of clinical treatment. In addition, we analyzed the effects of different concentrations of Tam on TAM-R cells by cell counting. Furthermore, the crosstalk between the stimulatory G protein α subunit (Gαs) and the activation of ERK1/2 and AKT in TAM-R cells was examined by small interfering RNA (siRNA) and immunoblotting methods. Low-dose Tam was found to act as an estrogen agonist via stimulation of the ERK1/2 signaling pathway, resulting in acquired resistance to Tam, whereas high-dose Tam inhibited TAM-R cell growth by blocking the activation of ERK1/2 and AKT. Moreover, Gαs was involved in Tam resistance in breast cancer cells. Taken together, our study demonstrated a dose-dependent growth response to Tam in TAM-R cells, which will promote the understanding of the importance of the appropriate use and dosage of Tam in the clinic.

show abstract

Section: Discussionmentioning

confidence: 96%

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Quite a few reports have presented a plausible explanation for endocrinal breast cancer therapy in post-menopausal women where a non-significant response to estrogen receptor-positive MCF-7 breast tumors was observed. PoMx exhibiting anticancer properties were successfully tested at a concentration of 300 mg/ml in combination with 1 mM tamoxifen to sensitize and enhance the activity of the latter, thereby inhibiting resistant MCF-7 cell proliferation (Aiyer et al, 2012;Banerjee et al, 2011).…”

Section: Breast Cancermentioning

confidence: 99%

Pomegranate peel and fruit extracts: A review of potential anti-inflammatory and anti-infective effects

Ismail

Sestili

Akhtar

2012

Journal of Ethnopharmacology

492

292

View full text Add to dashboard Cite

“…Subsequently, it was demonstrated that pomegranate fruit extracts enhance the action of the anti-estrogen tamoxifen in breast cancer cells [9]. Polyphenols also inhibit the expression of genes codifying for key androgen-synthesizing enzymes and androgen receptors [10] and EA was found to affect the growth, motility and invasiveness of androgen-independent prostate cancer [11].…”

Section: Introductionmentioning

confidence: 99%

Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth

et al. 2016

View full text Add to dashboard Cite

Ellagic acid (EA) is a polyphenolic compound that can be found as a naturally occurring hydrolysis product of ellagitannins in pomegranates, berries, grapes, green tea and nuts. Previous studies have reported the antitumor properties of EA mainly using in vitro models. No data are available about EA influence on bladder cancer cell invasion of the extracellular matrix triggered by vascular endothelial growth factor-A (VEGF-A), an angiogenic factor associated with disease progression and recurrence, and tumor growth in vivo. In this study, we have investigated EA activity against four different human bladder cancer cell lines (i.e., T24, UM-UC-3, 5637 and HT-1376) by in vitro proliferation tests (measuring metabolic and foci forming activity), invasion and chemotactic assays in response to VEGF-A and in vivo preclinical models in nude mice. Results indicate that EA exerts anti-proliferative effects as a single agent and enhances the antitumor activity of mitomycin C, which is commonly used for the treatment of bladder cancer. EA also inhibits tumor invasion and chemotaxis, specifically induced by VEGF-A, and reduces VEGFR-2 expression. Moreover, EA down-regulates the expression of programmed cell death ligand 1 (PD-L1), an immune checkpoint involved in immune escape. EA in vitro activity was confirmed by the results of in vivo studies showing a significant reduction of the growth rate, infiltrative behavior and tumor-associated angiogenesis of human bladder cancer xenografts. In conclusion, these results suggest that EA may have a potential role as an adjunct therapy for bladder cancer.

show abstract

Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells

Cited by 26 publications

References 24 publications

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways

Dose-dependent effect of tamoxifen in tamoxifen-resistant breast cancer cells via stimulation by the ERK1/2 and AKT signaling pathways

Pomegranate peel and fruit extracts: A review of potential anti-inflammatory and anti-infective effects

Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth

Contact Info

Product

Resources

About